DOCSLIB.ORG

Technetium-99M Radiopharmaceuticals: Status and Trends

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

IAEA RADIOISOTOPES AND RADIOPHARMACEUTICALS SERIES No. 1 This publication provides a broad overview of the current status and future prospects of technetium-99m (99mTc) radiopharmaceuticals, including a description of the most Radiopharmaceuticals: Status and Trends Technetium-99m advanced chemical techniques for labelling biomolecules and synthesizing suitable multifunctional ligands. It also reviews the most recent applications of 99mTc agents for monitoring different biological processes. Various subfields of clinical relevance are identified where 99mTc radiopharmaceuticals will continue to have a significant impact on nuclear medicine, such as cardiology, oncology, neurology, infection/inflammation, and gene expression. Technetium-99m Radiopharmaceuticals: Status and Trends INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA ISBN 978–92–0–103509–7 ISSN 2077–6462 Atoms for Peace Atoms for Peace 09-11441_P1405_cover.indd 1 2010-01-14 11:02:13 RELATED PUBLICATIONS IAEA RADIOISOTOPES AND RADIOPHARMACEUTICALS SERIES PUBLICATIONS CYCLOTRON PRODUCED RADIONUCLIDES: GUIDELINES FOR SETTING UP A FACILITY One of the main objectives of the IAEA Radioisotope Production and Radiation Technology Technical Reports Series No. 471 programme is to enhance the expertise and capability of IAEA Member States in deploying STI/DOC/010/471 (213 pp.; 2009) emerging radioisotope products and generators for medical and industrial applications in order to ISBN 978–92–0–103109–9 Price: €45.00 meet national needs as well as to assimilate new developments in radiopharmaceuticals for diagnostic and therapeutic applications. This will ensure local availability of these applications THERAPEUTIC RADIONUCLIDE GENERATORS: within a framework of quality assurance. 90SR/90Y AND 188W/188RE GENERATORS Publications in the IAEA Radioisotopes and Radiopharmaceuticals Series provide information in the areas of: reactor and accelerator produced radioisotopes, generators and sealed Technical Reports Series No. 470 sources development/production for medical and industrial uses; radiopharmaceutical sciences, STI/DOC/010/470 (233 pp.; 2009) including radiochemistry, radiotracer development, production methods and quality assurance/ ISBN 978–92–0–111408–2 Price: €45.00 quality control (QA/QC). The publications have a broad readership and are aimed at meeting the needs of scientists, engineers, researchers, teachers and students, laboratory professionals, and CYCLOTRON PRODUCED RADIONUCLIDES: instructors. International experts assist the IAEA Secretariat in drafting and reviewing these PHYSICAL CHARACTERISTICS AND PRODUCTION METHODS publications. Some of the publications in this series may also be endorsed or co-sponsored by Technical Reports Series No. 468 international organizations and professional societies active in the relevant fields. STI/DOC/010/468 (279 pp.; 2009) There are two categories of publications: the IAEA Radioisotopes and Radiopharmaceuticals Series and IAEA Radioisotopes and Radiopharmaceuticals Reports. ISBN 978–92–0–106908–5 Price: €52.00 IAEA RADIOISOTOPES AND RADIOPHARMACEUTICALS SERIES TECHNETIUM RADIOPHARMACEUTICALS: Publications in this category present guidance information or methodologies and analyses of MANUFACTURE OF KITS long term validity, for example protocols, guidelines, codes, standards, quality assurance manuals, Technical Reports Series No. 466 best practices and high level technological and educational material. STI/DOC/010/466 (202 pp.; 2008) ISBN 978–92–0–100408–6 Price: €50.00 IAEA RADIOISOTOPES AND RADIOPHARMACEUTICALS REPORTS In this category, publications complement information published in the IAEA Radioisotopes CYCLOTRON PRODUCED RADIONUCLIDES: and Radiopharmaceuticals Series in areas of the: development and production of radioisotopes and generators for medical and industrial applications; and development, production and QA/QC of PRINCIPLES AND PRACTICE diagnostic and therapeutic radiopharmaceuticals. These publications include reports on current Technical Reports Series No. 465 issues and activities such as technical meetings, the results of IAEA coordinated research projects, STI/DOC/010/465 (230 pp.; 2008) interim reports on IAEA projects, and educational material compiled for IAEA training courses ISBN 978–92–0–100208–2 Price: €45.00 dealing with radioisotope and radiopharmaceutical related subjects. In some cases, these reports may provide supporting material relating to publications issued in the IAEA Radioisotopes and COMPARATIVE EVALUATION OF THERAPEUTIC Radiopharmaceuticals Series. RADIOPHARMACEUTICALS All of these publications can be downloaded cost free from the IAEA web site: Technical Reports Series No. 458 STI/DOC/010/458 (310 pp.; 2007) http://www.iaea.org/Publications/index.html ISBN 92–0–115106–3 Price: €56.00 Further information is available from: LABELLING OF SMALL BIOMOLECULES USING NOVEL TECHNETIUM-99M CORES Sales and Distribution Unit International Atomic Energy Agency Technical Reports Series No. 459 Vienna International Centre STI/DOC/010/459 (312 pp.; 2007) PO Box 100 ISBN 92–0–101607–7 Price: €70.00 1400 Vienna, Austria TRENDS IN RADIOPHARMACEUTICALS (2 volumes) Readers are invited to provide feedback to the IAEA on these publications. Information may STI/PUB/1294 (Vol. 1: 408 pp.; Vol. 2: 464 pp.; 2007) be provided through the IAEA web site, by mail at the address given above, or by email to: ISBN 92–0–101707–3 Price: €120.00 [email protected] www.iaea.org/books 09-11441_P1405_cover.indd 2 2010-01-14 11:02:14 TECHNETIUM-99m RADIOPHARMACEUTICALS: STATUS AND TRENDS The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GHANA NORWAY ALBANIA GREECE OMAN ALGERIA GUATEMALA PAKISTAN ANGOLA HAITI PALAU ARGENTINA HOLY SEE PANAMA ARMENIA HONDURAS PARAGUAY AUSTRALIA HUNGARY PERU AUSTRIA ICELAND PHILIPPINES AZERBAIJAN INDIA POLAND BAHRAIN INDONESIA PORTUGAL BANGLADESH IRAN, ISLAMIC REPUBLIC OF QATAR BELARUS IRAQ REPUBLIC OF MOLDOVA BELGIUM IRELAND ROMANIA BELIZE ISRAEL RUSSIAN FEDERATION BENIN ITALY BOLIVIA JAMAICA SAUDI ARABIA BOSNIA AND HERZEGOVINA JAPAN SENEGAL BOTSWANA JORDAN SERBIA BRAZIL KAZAKHSTAN SEYCHELLES BULGARIA KENYA SIERRA LEONE BURKINA FASO KOREA, REPUBLIC OF SINGAPORE BURUNDI KUWAIT SLOVAKIA CAMBODIA KYRGYZSTAN SLOVENIA CAMEROON LATVIA SOUTH AFRICA CANADA LEBANON SPAIN CENTRAL AFRICAN LESOTHO SRI LANKA REPUBLIC LIBERIA SUDAN CHAD LIBYAN ARAB JAMAHIRIYA SWEDEN CHILE LIECHTENSTEIN SWITZERLAND CHINA LITHUANIA SYRIAN ARAB REPUBLIC COLOMBIA LUXEMBOURG TAJIKISTAN CONGO MADAGASCAR THAILAND COSTA RICA MALAWI THE FORMER YUGOSLAV CÔTE D’IVOIRE MALAYSIA REPUBLIC OF MACEDONIA CROATIA MALI TUNISIA CUBA MALTA TURKEY CYPRUS MARSHALL ISLANDS UGANDA CZECH REPUBLIC MAURITANIA UKRAINE DEMOCRATIC REPUBLIC MAURITIUS UNITED ARAB EMIRATES OF THE CONGO MEXICO DENMARK MONACO UNITED KINGDOM OF DOMINICAN REPUBLIC MONGOLIA GREAT BRITAIN AND ECUADOR MONTENEGRO NORTHERN IRELAND EGYPT MOROCCO UNITED REPUBLIC EL SALVADOR MOZAMBIQUE OF TANZANIA ERITREA MYANMAR UNITED STATES OF AMERICA ESTONIA NAMIBIA URUGUAY ETHIOPIA NEPAL UZBEKISTAN FINLAND NETHERLANDS VENEZUELA FRANCE NEW ZEALAND VIETNAM GABON NICARAGUA YEMEN GEORGIA NIGER ZAMBIA GERMANY NIGERIA ZIMBABWE The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters, New York; it entered into force on 29 July 1957. The Headquarters of the Agency are situated in Vienna. Its principal objective is “to accelerate and enlarge the contribution of atomic energy to peace, health and prosperity throughout the world’’. IAEA RADIOISOTOPES AND RADIOPHARMACEUTICALS SERIES No. 1 TECHNETIUM-99m RADIOPHARMACEUTICALS: STATUS AND TRENDS INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA, 2009 COPYRIGHT NOTICE All IAEA scientific and technical publications are protected by the terms of the Universal Copyright Convention as adopted in 1952 (Berne) and as revised in 1972 (Paris). The copyright has since been extended by the World Intellectual Property Organization (Geneva) to include electronic and virtual intellectual property. Permission to use whole or parts of texts contained in IAEA publications in printed or electronic form must be obtained and is usually subject to royalty agreements. Proposals for non-commercial reproductions and translations are welcomed and considered on a case-by-case basis. Enquiries should be addressed to the IAEA Publishing Section at: Sales and Promotion, Publishing Section International Atomic Energy Agency Vienna International Centre PO Box 100 1400 Vienna, Austria fax: +43 1 2600 29302 tel.: +43 1 2600 22417 email: [email protected] http://www.iaea.org/books © IAEA, 2009 Printed by the IAEA in Austria December 2009 STI/PUB/1405 IAEA Library Cataloguing in Publication Data Technetium-99m radiopharmaceuticals : status and trends. — Vienna : International Atomic Energy Agency, 2009. p. ; 24 cm. — (IAEA radioisotopes and radiopharmaceuticals series, ISSN 2077-6462 ; no. 1) STI/PUB/1405 ISBN 978–92–0–103509–7 Includes bibliographical references. 1. Technetium — Isotopes – Diagnostic use. 2. Radiopharmaceuticals. I. International Atomic Energy Agency. II. Series. IAEAL 09–00617 FOREWORD Technetium-99m radiopharmaceuticals are applied in morphological and dynamic imaging of many organs in the body, to diagnose various diseases. It is estimated that about 25 million diagnostic investigations are performed annually using this single isotope. It is expected that current applications using 99mTc radiopharmaceuticals in renal, hepatic, hepatobiliary, bone, cardiac
Recommended publications
  • Managing Terrorism Or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: a Comprehensive Review

    Managing Terrorism Or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: a Comprehensive Review

    Int. J. Environ. Res. Public Health 2014, 11, 4158-4200; doi:10.3390/ijerph110404158 OPEN ACCESS International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph Review Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review Eric R. Braverman 1,2,3, Kenneth Blum 1,2,*, Bernard Loeffke 2, Robert Baker 4, 5, Florian Kreuk 2, Samantha Peiling Yang 6 and James R. Hurley 7 1 Department of Psychiatry, College of Medicine, University of Florida and McKnight Brain Institute, Gainesville, FL 32610, USA; E-Mail: [email protected] 2 Department of Clinical Neurology, PATH Foundation NY, New York, NY 10010, USA; E-Mails: [email protected] (B.L.); [email protected] (F.K.) 3 Department of Neurosurgery, Weill-Cornell Medical College, New York, NY 10065, USA 4 Department of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA; E-Mail: [email protected] 5 Natural Science Research Laboratory, Museum of Texas Tech University, Lubbock, TX 79409, USA 6 Department of Endocrinology, National University Hospital of Singapore, Singapore 119228; E-Mail: [email protected] 7 Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-646-367-7411 (ext. 123); Fax: +1-212-213-6188. Received: 5 February 2014; in revised form: 26 March 2014 / Accepted: 28 March 2014 / Published: 15 April 2014 Abstract: Chernobyl demonstrated that iodine-131 (131I) released in a nuclear accident can cause malignant thyroid nodules to develop in children within a 300 mile radius of the incident.
  • Landscape Analysis of Phase 2/3 Clinical Trials of Targeted

    Landscape Analysis of Phase 2/3 Clinical Trials of Targeted

    Journal of Nuclear Medicine, published on February 12, 2021 as doi:10.2967/jnumed.120.258103 Landscape analysis of Phase 2/3 clinical trials for Targeted Radionuclide Therapy Erik Mittra1, Amanda Abbott2, and Lisa Bodei3 Affiliations 1. Division of Nuclear Medicine & Molecular Imaging, Oregon Health & Science University, Portland, OR 2. Clinical Trials Network, Society of Nuclear Medicine & Molecular Imaging, Reston, VA 3. Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY Word count without figure: 880 Word count with figure: 971 Key Words: radioisotope therapy, radiopharmaceutical therapy and radioligand therapy Text Within Nuclear Medicine, theranostics has revitalized the field of Targeted Radionuclide Therapy (TRT) and there is a growing number of investigator-initiated and industry-sponsored clinical trials of TRT. This article summarizes the current trials available in the NIH database, the largest trial repository, to provide both an overview of the current landscape and a glimpse towards an undeniably exciting future of theranostics. This landscape analysis was completed by searching the terms “radionuclide therapy”, “radioisotope therapy”, “radiopharmaceutical therapy” and “radioligand therapy” on ClinicalTrials.gov in November 2020. Other terms may provide different results. Phase 1/2, 2, and 3 trials that are currently recruiting and those not yet recruiting were included. Studies. Overall, the results showed 42 clinical trials including 13 Phase 1/2, 26 Phase 2, and three Phase 3. Given this range of phases, the planned enrollment varies widely from 10-813, with an average of 147 participants. Five different radioisotopes, 12 ligands or targets, and 11 different cancer types are represented (Figure 1).
  • Radioisotopes and Radiopharmaceuticals

    Radioisotopes and Radiopharmaceuticals

    RADIOISOTOPES AND RADIOPHARMACEUTICALS Radioisotopes are the unstable form of an element that emits radiation to become a more stable form — they have certain special attributes. These make radioisotopes useful in areas such as medicine, where they are used to develop radiopharmaceuticals, as well as many other industrial applications. THE PRODUCTION OF TECHNETIUM-99m RADIOPHARMACEUTICALS: ONE POSSIBLE ROUTE IRRADIATED U-235 99 TARGETS MO PROCESSING FACILITY HOSPITAL RADIOPHARMACY (MIXING WITH BIOLOGICAL MOLECULES THAT BIND AT DIFFERENT LOCATIONS IN THE 99mTC IS IDEAL FOR DIAGNOSTICS BECAUSE OF BODY, SUPPORTING A WIDE ITS SHORT HALF-LIFE (6 HOURS) AND IDEAL GAMMA EMISSION RANGE OF MEDICAL NUCLEAR APPLICATIONS) REACTOR: 6 HOURS MAKES DISTRIBUTION DIFFICULT 99MO BULK LIQUID TARGET ITS PARENT NUCLIDE, MOLYBDENUM-99, IS PRODUCED; ITS HALF-LIFE (66 HOURS) MAKES 99 99m IRRADIATION IT SUITABLE FOR TRANSPORT MO/ TC GENERATORS 99MO/99mTC GENERATORS ARE PRODUCED AND DISTRIBUTED AROUND THE GLOBE 99MO/99TC GENERATOR MANUFACTURER Radioisotopes can occur naturally or be produced artificially, mainly in research reactors and accelerators. They are used in various fields, including nuclear medicine, where radiopharmaceuticals play a major role. Radiopharmaceuticals are substances that contain a radioisotope, and have properties that make them effective markers in medical diagnostic or therapeutic procedures. The chemical presence of radiopharmaceuticals can relay detailed information to medical professionals that can help in diagnoses and treatments. Eighty percent of all diagnostic medical scans worldwide use 99mTc, and its availability, at present, is dependent on the production of 99Mo in research reactors. Globally, the number of medical procedures involving the use of radioisotopes is growing, with an increasing emphasis on radionuclide therapy using radiopharmaceuticals for the treatment of cancer..
  • OPERATIONAL GUIDANCE on HOSPITAL RADIOPHARMACY: a SAFE and EFFECTIVE APPROACH the Following States Are Members of the International Atomic Energy Agency

    OPERATIONAL GUIDANCE on HOSPITAL RADIOPHARMACY: a SAFE and EFFECTIVE APPROACH the Following States Are Members of the International Atomic Energy Agency

    OPERATIONAL GUIDANCE ON HOSPITAL RADIOPHARMACY: A SAFE AND EFFECTIVE APPROACH The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GUATEMALA PAKISTAN ALBANIA HAITI PALAU ALGERIA HOLY SEE PANAMA ANGOLA HONDURAS PARAGUAY ARGENTINA HUNGARY PERU ARMENIA ICELAND PHILIPPINES AUSTRALIA INDIA POLAND AUSTRIA INDONESIA PORTUGAL AZERBAIJAN IRAN, ISLAMIC REPUBLIC OF QATAR BANGLADESH IRAQ REPUBLIC OF MOLDOVA BELARUS IRELAND ROMANIA BELGIUM ISRAEL RUSSIAN FEDERATION BELIZE ITALY SAUDI ARABIA BENIN JAMAICA SENEGAL BOLIVIA JAPAN SERBIA BOSNIA AND HERZEGOVINA JORDAN SEYCHELLES BOTSWANA KAZAKHSTAN BRAZIL KENYA SIERRA LEONE BULGARIA KOREA, REPUBLIC OF SINGAPORE BURKINA FASO KUWAIT SLOVAKIA CAMEROON KYRGYZSTAN SLOVENIA CANADA LATVIA SOUTH AFRICA CENTRAL AFRICAN LEBANON SPAIN REPUBLIC LIBERIA SRI LANKA CHAD LIBYAN ARAB JAMAHIRIYA SUDAN CHILE LIECHTENSTEIN SWEDEN CHINA LITHUANIA SWITZERLAND COLOMBIA LUXEMBOURG SYRIAN ARAB REPUBLIC COSTA RICA MADAGASCAR TAJIKISTAN CÔTE D’IVOIRE MALAWI THAILAND CROATIA MALAYSIA THE FORMER YUGOSLAV CUBA MALI REPUBLIC OF MACEDONIA CYPRUS MALTA TUNISIA CZECH REPUBLIC MARSHALL ISLANDS TURKEY DEMOCRATIC REPUBLIC MAURITANIA UGANDA OF THE CONGO MAURITIUS UKRAINE DENMARK MEXICO UNITED ARAB EMIRATES DOMINICAN REPUBLIC MONACO UNITED KINGDOM OF ECUADOR MONGOLIA GREAT BRITAIN AND EGYPT MONTENEGRO NORTHERN IRELAND EL SALVADOR MOROCCO ERITREA MOZAMBIQUE UNITED REPUBLIC ESTONIA MYANMAR OF TANZANIA ETHIOPIA NAMIBIA UNITED STATES OF AMERICA FINLAND NEPAL URUGUAY FRANCE NETHERLANDS UZBEKISTAN GABON NEW ZEALAND VENEZUELA GEORGIA NICARAGUA VIETNAM GERMANY NIGER YEMEN GHANA NIGERIA ZAMBIA GREECE NORWAY ZIMBABWE The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters, New York; it entered into force on 29 July 1957. The Headquarters of the Agency are situated in Vienna.
  • Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors

    Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors

    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2012 Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors Marisa Rosenberg Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2715 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. ANTINOCICEPTIVE EFFECTS OF MONOAMINE REUPTAKE INHIBITORS IN ASSAYS OF PAIN-STIMULATED AND PAIN-DEPRESSED BEHAVIOR A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University By Marisa B. Rosenberg Bachelor of Science, Temple University, 2008 Advisor: Sidney Stevens Negus, Ph.D. Professor, Department of Pharmacology/Toxicology Virginia Commonwealth University Richmond, VA May, 2012 Acknowledgement First and foremost, I’d like to thank my advisor Dr. Steven Negus, whose unwavering support, guidance and patience throughout my graduate career has helped me become the scientist I am today. His dedication to education, learning and the scientific process has instilled in me a quest for knowledge that I will continue to pursue in life. His thoroughness, attention to detail and understanding of pharmacology has been exemplary to a young person like me just starting out in the field of science. I’d also like to thank all of my committee members (Drs.
  • Technetium in the Geologic Environment a Literature Survey

    Technetium in the Geologic Environment a Literature Survey

    Report Prav 4.28 TECHNETIUM IN THE GEOLOGIC ENVIRONMENT A LITERATURE SURVEY B Torstenfel t B Al lard K Andersson U Olofsson Department of Nuclear Chemistry Chalmers University of Technology Göteborg, Sweden July 1981 CONTENTS Page Introduction 1 The technetium metal 2 Technetiums redox properties and complexes 3 Oxidation state +VII 4 Oxidation states +VI and +V 7 Oxidation state +IV 7 Oxidation states +1 - +111 14 The accumulation of Tc in the Pood chain 14 The chemistry of Tc in connection with the final storage of spent nuclear fuel 15 Si'"otion of Tc in rock 15 - t tion of Tc in clay and soil 20 yjtion of Tc in sea bottom sediments 22 ?a "ption and migration of Tc in Oklo 22 /iferences 23 INTRODUCTION Technetium belongs to the transition metals in the second series of the d-grcup. It is a member of the VII B group together with manganese and rehnium.1»2'3'4.5 According to the common behaviour of the elements in the periodic system, Tc would have an electron structure of the outer shell like Mn and Re, given as 4d55s2 1, but Tc is one of the exceptions and, unlike Mn and Re, have the structure 4d653! (= supereiectron configuration of the krypton atom).2 This electron structure makes it possible for Tc to have VIII oxidation states,from +VII to -I. The most stable oxidation states are +VII, +IV and 01. Technetiums chemical properties is closer to rhenium than to manganese2-3'4-5. It is characterized by a weak tendency towards reduction, formation of slow-spin complexes and cluster compounds with low degree of oxidation2.
  • Monitored Natural Attenuation of Inorganic Contaminants in Ground

    Monitored Natural Attenuation of Inorganic Contaminants in Ground

    Monitored Natural Attenuation of Inorganic Contaminants in Ground Water Volume 3 Assessment for Radionuclides Including Tritium, Radon, Strontium, Technetium, Uranium, Iodine, Radium, Thorium, Cesium, and Plutonium-Americium EPA/600/R-10/093 September 2010 Monitored Natural Attenuation of Inorganic Contaminants in Ground Water Volume 3 Assessment for Radionuclides Including Tritium, Radon, Strontium, Technetium, Uranium, Iodine, Radium, Thorium, Cesium, and Plutonium-Americium Edited by Robert G. Ford Land Remediation and Pollution Control Division Cincinnati, Ohio 45268 and Richard T. Wilkin Ground Water and Ecosystems Restoration Division Ada, Oklahoma 74820 Project Officer Robert G. Ford Land Remediation and Pollution Control Division Cincinnati, Ohio 45268 National Risk Management Research Laboratory Office of Research and Development U.S. Environmental Protection Agency Cincinnati, Ohio 45268 Notice The U.S. Environmental Protection Agency through its Office of Research and Development managed portions of the technical work described here under EPA Contract No. 68-C-02-092 to Dynamac Corporation, Ada, Oklahoma (David Burden, Project Officer) through funds provided by the U.S. Environmental Protection Agency’s Office of Air and Radiation and Office of Solid Waste and Emergency Response. It has been subjected to the Agency’s peer and administrative review and has been approved for publication as an EPA document. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. All research projects making conclusions or recommendations based on environmental data and funded by the U.S. Environmental Protection Agency are required to participate in the Agency Quality Assurance Program. This project did not involve the collection or use of environmental data and, as such, did not require a Quality Assurance Plan.
  • Epilepsy & Seizure

    Epilepsy & Seizure

    Epilepsy & Seizure Journal of Japan Epilepsy Society Vol.4 No.1 (2011) pp.15-25 Original Article Usefulness of 123I-iomazenil SPECT for childhood focal epilepsies 1) 1) 1) 1) Kentaro Okamoto, MD , Hirokazu Oguni, MD , Yoshiko Hirano, MD , Makiko Osawa, MD 1Department of Pediatrics, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan Key words: focal epilepsy, children, 123I-iomazenil SPECT, epileptic foci Published online July 29, 2011 Abstract Purpose: We investigated the usefulness of obtained from visualization of IMZ-SPECT 123I-iomazenil (IMZ-) SPECT to detect epilep- images and those speculated based on a com- tic foci in children with symptomatic focal bination of clinical manifestations, EEG find- epilepsy (SFE). ings, and brain MRI. We then verified the Subjects: 21 children with SFE who under- concordance of the results between the two went IMZ-SPECT to identify the epileptic fo- methods. cus were studied. Results: There was concordance in both later- Methods: We retrospectively compared the alization and localization in 9/12 patients with localization and lateralization of epileptic foci temporal lobe epilepsy (75%), in 2/5 patients Correspondence to: Hirokazu Oguni, MD, Department of Pediatrics, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162, Japan Tel. 81-3-3353-8111, Fax. 81-3-5269-7338, [email protected] 15 Kentaro Okamoto, et al. IMZ-SPECT for childhood epilepsy with frontal lobe epilepsy (40%), and in 2/4 interictal/ictal cerebral blood flow single pho- patients with parieto-occipital lobe epilepsy ton emission computed tomography (SPECT) (50%).
  • Dopamine Reuptake Transporter (DAT) “Inverse Agonism” E Anovel 66 2 67 3 Hypothesis to Explain the Enigmatic Pharmacology of Cocaine 68 4 * 69 5 Q5 David J

    Dopamine Reuptake Transporter (DAT) “Inverse Agonism” E Anovel 66 2 67 3 Hypothesis to Explain the Enigmatic Pharmacology of Cocaine 68 4 * 69 5 Q5 David J

    NP5526_proof ■ 24 June 2014 ■ 1/22 Neuropharmacology xxx (2014) 1e22 55 Contents lists available at ScienceDirect 56 57 Neuropharmacology 58 59 60 journal homepage: www.elsevier.com/locate/neuropharm 61 62 63 64 65 1 Dopamine reuptake transporter (DAT) “inverse agonism” e Anovel 66 2 67 3 hypothesis to explain the enigmatic pharmacology of cocaine 68 4 * 69 5 Q5 David J. Heal , Jane Gosden, Sharon L. Smith 70 6 71 RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK 7 72 8 73 9 article info abstract 74 10 75 11 76 Article history: The long held view is cocaine's pharmacological effects are mediated by monoamine reuptake inhibition. 12 Available online xxx However, drugs with rapid brain penetration like sibutramine, bupropion, mazindol and tesofensine, 77 13 which are equal to or more potent than cocaine as dopamine reuptake inhibitors, produce no discernable 78 14 Keywords: subjective effects such as drug “highs” or euphoria in drug-experienced human volunteers. Moreover 79 15 Cocaine they are dysphoric and aversive when given at high doses. In vivo experiments in animals demonstrate 80 16 Dopamine reuptake inhibitor that cocaine's monoaminergic pharmacology is profoundly different from that of other prescribed 81 Dopamine releasing agent 17 monoamine reuptake inhibitors, with the exception of methylphenidate. These findings led us to 82 Dopamine transporter fi 18 Inverse agonist conclude that the highly unusual, stimulant pro le of cocaine and related compounds, eg methylphe- 83 19 DAT inverse agonist nidate, is not mediated by monoamine reuptake inhibition alone. 84 We describe the experimental findings which suggest cocaine serves as a negative allosteric 20 Novel mechanism 85 21 modulator to alter the function of the dopamine reuptake transporter (DAT) and reverse its direction of fi 86 22 transport.
  • RADIO PHARMACEUTICALS  Production Control  Safety Precautions  Applications  Storage

    RADIO PHARMACEUTICALS  Production Control  Safety Precautions  Applications  Storage

    RADIO PHARMACEUTICALS Production control Safety precautions Applications Storage. Presented by: K. ARSHAD AHMED KHAN M.Pharm, (Ph.D) Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research [RIPER] Anantapur. 1 DEFINITION: Radiopharmaceuticals are the radioactive substances or radioactive drugs for diagnostic or therapeutic interventions. or Radiopharmaceuticals are medicinal formulations containing radioisotopes which are safe for administration in humans for diagnosis or for therapy. 2 COMPOSITION: • A radioactive isotope that can be injected safely into the body, and • A carrier molecule which delivers the isotope to the area to be treated or examined. 3 USAGE/WORKING: 4 BASICS Nuclide: This is a particular nuclear species characterized by its atomic number (No. of protons) and mass 12 23 number (No. of protons + neutrons). 6C , 11Na Isotopes: These are nuclides with same atomic number and different mass number. 1 2 3 Hydrogen has 3 isotopes --- 1H , 1H , 1H . 10 11 12 13 14 Carbon has 5 isotopes ------6C , 6C , 6C , 6C , 6C . 5 • ISOTOPES MAY BE STABLE OR UNSTABLE. • The nucleus is unstable if the number of neutrons is less or greater than the number of protons. • If they are unstable, they under go radioactive decay or disintegration and are known as radioactive isotopes/ radioactive nuclides. Radioactivity: The property of unstable nuclides of emitting radiation by spontaneous transformation of nuclei into other nuclides is called radioactivity. •Radioactive isotopes emit radiations or rays like α, β, γ rays. 6 PRODUCTION CONTROL 7 8 9 10 11 12 13 14 15 Radiopharmaceuticals production occurs in machines like 1. Cyclotron (low energy, high energy) 2.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Imaging in Parkinson's Disease

    Imaging in Parkinson's Disease

    Clinical Medicine 2016 Vol 16, No 4: 371–5 CME MOVEMENT DISORDERS I m a g i n g i n P a r k i n s o n ’ s d i s e a s e Authors: G e n n a r o P a g a n o , A F l a v i a N i c c o l i n i B a n d M a r i o s P o l i t i s C The clinical presentation of Parkinson’s disease (PD) Abnormal intra-neuronal (Lewy bodies) and intra-neuritic is heterogeneous and overlaps with other conditions, (Lewy neurites) deposits of fibrillary aggregates are currently including the parkinsonian variant of multiple system considered the key neuropathological alterations in PD. atrophy (MSA-P), progressive supranuclear palsy (PSP) and The majority of these aggregates, mainly composed of alpha essential tremor. Imaging of the brain in patients with (α)−synuclein, are located at presynaptic level and impair ABSTRACT parkinsonism has the ability to increase the accuracy of axonal trafficking, resulting in a series of noxious events that differential diagnosis. Magnetic resonance imaging (MRI), cause neuronal damage to the substantia nigra pars compacta single photon emission computed tomography (SPECT) and with a subsequent dopaminergic denervation of the striatum. positron emission tomography (PET) allow brain imaging The cardinal motor features of PD (bradykinesia and rigidity, of structural, functional and molecular changes in vivo in with or without resting tremor) manifest after a substantial patients with PD. Structural MRI is useful to differentiate denervation of substantia nigra, which is associated with about PD from secondary and atypical forms of parkinsonism.